SBIR Phase I: Creation of antimicrobial MyoMatrix for functional muscle regeneration in a porcine model of volumetric muscle loss

SBIR 第一阶段：创建抗菌 MyoMatrix，用于猪体积肌肉损失模型中的功能性肌肉再生

• 批准号: 2304420
• 负责人: Gabriel Haas
• 金额: $ 27.5万
• 依托单位: GENASSIST INC
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-05-01 至 2025-04-30
• 项目状态: 未结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2304420&HistoricalAwards=false
• 关键词: SBIR; Phase; Creation; antimicrobial; MyoMatrix

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project is to develop an antimicrobial muscle-regenerating biomaterial into a commercial-ready product and address volumetric muscle loss injuries. In the context of defense medicine, severe muscle trauma often occurs in environments where external factors such as sterility are not well-controlled. This project is expected to demonstrate antimicrobial properties of this novel muscle-regenerating biomaterial to enable use in these environments. If successful, the broader societal and economic impacts of antimicrobial muscle-regenerating biomaterials are staggering. Volumetric muscle loss affects tens of millions of victims each year. Sixty percent of patients are left untreated, 30% receive a muscle flap transplant, and 10% of injured limbs are amputated. Total average lifetime costs for amputation now total over $700,000. Improved clinical outcomes resulting from the implementation of this technology could lead to hundreds of thousands of dollars in savings over the course of each recipient's lifetime.This Small Business Innovation Research (SBIR) Phase I project demonstrates significant advances over the existing standard of care for the treatment of volumetric muscle loss, for which no treatment currently exists. The joint loss of cells and extracellular matrix creates an environment where muscle regeneration cannot occur, leading to muscle collapse and atrophy over time. This project effectively replaces the extracellular matrix lost in volumetric muscle loss and creates an environment where satellite cells may proliferate and differentiate into new muscle tissue. A technical concern raised by clinicians, especially those who work in austere environments in military medicine, is the risk of infection caused by implanting a foreign substance into a wound bed. To address this, Technical Objective 1 will focus on incorporating antibacterial agents to optimize the scaffold’s ability to promote muscle regeneration while also having an antibacterial effect. Structural and mechanical properties will be assessed, cellular viability ensured, muscle cell quality evaluated, and antibacterial properties measured. Technical Objective 2 aims to investigate these outcomes with a pilot porcine model of muscle trauma. It is anticipated that the proposed antimicrobial biomaterial will both combat the risk of infection and effectively regenerate functional muscle in traumatic muscle injuries.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小型企业创新研究（SBIR）I阶段项目的更广泛的影响/商业潜力是将抗菌肌肉再生生物材料开发为商业就绪产品，并解决容量的肌肉损失损伤。在国防医学的背景下，严重的肌肉创伤经常发生在不育不育等外部因素的环境中。预计该项目将证明这种新型肌肉再生生物材料的抗菌特性，以在这些环境中使用。如果成功，抗菌肌肉再生的生物材料对社会和经济的广泛影响令人震惊。体积肌肉损失每年会影响数千万的受害者。 60％的患者未经治疗，30％接受肌肉皮瓣移植，肢体受伤的10％被截肢。截肢的总平均寿命成本总计超过$ 700,000。实施该技术导致的临床结果的改善可能会导致每位收件人一生的储蓄数十万美元的节省。这项小型企业创新研究（SBIR）I阶段项目项目在现有的护理标准方面取得了重大进展，用于治疗体积肌肉损失的治疗，目前尚无治疗。细胞和细胞外基质的关节损失会产生无法发生肌肉再生的环境，从而导致肌肉塌陷和萎缩。该项目有效地取代了体积肌肉损失中损失的细胞外基质，并创建了一个环境，卫星细胞可能会增殖并分化为新的肌肉组织。临床医生提出的技术问题，尤其是那些在军事医学上严峻的环境中工作的人，是通过将异物植入伤口床引起的感染风险。为了解决这个问题，技术目标1将重点放在纳入抗菌剂，以优化脚手架促进肌肉再生的能力，同时还具有抗菌作用。将评估结构和机械性能，确保细胞活力，评估肌肉细胞质量以及测量的抗菌特性。技术目标2旨在通过肌肉创伤的试验猪模型来研究这些结果。可以预料，提出的抗菌生物材料将应对感染的风险，并有效地在创伤性肌肉损伤中再生功能性肌肉。这项奖项反映了NSF的法定任务，并被认为是通过基金会的知识分子优点和更广泛的影响审查标准来评估的支持。